Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation

Cellular and Molecular Life Sciences

Volumn 60, Issue 6, 2003, Pages 1118-1134

  Houten, S M ^a,c   Frenkel, J ^b   Waterham, H R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Autoinflammatory syndromes; Fever; Hyper IgD and periodic fever syndrome; Inflammation; Isoprenoid biosynthesis; Mevalonate kinase; Mevalonic aciduria

Indexed keywords

CHOLESTEROL; FARNESOL; GERANYLGERANIOL; ISOPRENOID; MEVALONATE KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ACIDURIA; BIOSYNTHESIS; CHOLESTEROL SYNTHESIS; ENZYME DEFICIENCY; FAMILIAL MEDITERRANEAN FEVER; FEVER; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA; INFLAMMATION; MEVALONATE KINASE DEFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0038724543     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-2296-4     Document Type: Review

References (144)

1. Casey P. J. and Seabra M. C. (1996) Protein prenyltransferases. J. Biol. Chem. 271: 5289-5292
2. Fielding C. J. and Fielding P. E. (2000) Cholesterol and caveolae: structural and functional relationships. Biochim. Biophys. Acta 1529: 210-222
3. Mann R. K. and Beachy P. A. (2000) Cholesterol modification of proteins. Biochim. Biophys. Acta 1529: 188-202
4. Schroepfer G. J. Jr (1981) Sterol biosynthesis. Annu. Rev. Biochem. 50: 585-621
5. Goldstein J. L. and Brown M. S. (1990) Regulation of the mevalonate pathway. Nature 343: 425-430
6. Houten S. M., Wanders R. J. and Waterham H. R. (2000) Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochim. Biophys. Acta 1529: 19-32
7. Yang D., Shipman L. W., Roessner C. A., Scott A. I. and Sacchettini J. C. (2002) Structure of the Methanococcus jannaschii mevalonate kinase, a member of the GHMP kinase superfamily. J. Biol. Chem. 277: 9462-9467
8. Fu Z., Wang M., Potter D., Miziorko H. M. and Kim J. J. (2002) The structure of a binary complex between a mammalian mevalonate kinase and ATP. J. Biol. Chem. 277: 18134-18142
9. Wang K. C. and Ohnuma S. (2000) Isoprenyl diphosphate synthases. Biochim. Biophys. Acta 1529: 33-48
10. Kandutsch A. A. and Russell A. E. (1960) Preputial gland tumor sterols: III. A metabolic pathway from lanosterol to cholesterol. J. Biol. Chem. 235: 2256-2261
11. Schroepfer G. J. Jr (1982) Sterol biosynthesis. Annu. Rev. Biochem. 51: 555-585
12. Bae S. H. and Paik Y. K. (1997) Cholesterol biosynthesis from lanosterol: development of a novel assay method and characterization of rat liver microsomal lanosterol delta 24-reductase. Biochem. J. 326: 609-616
13. Waterham H. R. and Wanders R. J. (2000) Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim. Biophys. Acta 1529: 340-356
14. Crick D. C., Waechter C. J. and Andres D. A. (1994) Utilization of geranylgeraniol for protein isoprenylation in C6 glial cells. Biochem Biophys. Res. Commun. 205: 955-961
15. Crick D. C., Andres D. A. and Waechter C. J. (1995) Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells. Biochem. Biophys. Res. Commun. 211: 590-599
16. Crick D. C., Andres D. A. and Waechter C. J. (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem. Biophys. Res. Commun. 237: 483-487
17. Laufs U., Marra D., Node K. and Liao J. K. (1999) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J. Biol. Chem. 274: 21926-21931
18. Parker R. A., Pearce B. C., Clark R. W., Gordon D. A. and Wright J. J. (1993) Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 268: 11230-11238
19. Correll C. C. and Edwards P. A. (1994) Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J. Biol. Chem. 269: 633-638
20. Bradfute D. L. and Simoni R. D. (1994) Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem. 269: 6645-6650
21. Correll C. C., Ng L. and Edwards P. A. (1994) Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269: 17390-17393
22. Bansal V. S. and Vaidya S. (1994) Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. Arch. Biochem. Biophys. 315: 393-399
23. Meigs T. E., Roseman D. S. and Simoni R. D. (1996) Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271: 7916-7922
24. Meigs T. E. and Simoni R. D. (1997) Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys. 345: 1-9
25. Keller R. K., Zhao Z., Chambers C. and Ness G. C. (1996) Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch. Biochem. Biophys. 328: 324-330
26. Miquel K., Pradines A., Terce F., Selmi S. and Favre G. (1998) Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J. Biol. Chem. 273: 26179-26186
27. Wright M. M., Henneberry A. L., Lagace T. A., Ridgway N. D. and McMaster C. R. (2001) Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. J. Biol. Chem. 276: 25254-25261
28. Miquel K., Pradines A. and Favre G. (1996) Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem. Biophys. Res. Commun. 225: 869-876
29. Thai L., Rush J. S., Maul J. E., Devarenne T., Rodgers D. L., Chappell J. et al. (1999) Farnesol is utilized for isoprenoid biosynthesis in plant cells via farnesyl pyrophosphate formed by successive monophosphorylation reactions. Proc. Natl. Acad. Sci. USA 96: 13080-13085
30. Westfall D., Aboushadi N., Shackelford J. E. and Krisans S. K. (1997) Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem. Biophys. Res. Commun. 230: 562-568
31. Bentinger M., Grunler J., Peterson E., Swiezewska E. and Dallner G. (1998) Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. Arch. Biochem. Biophys. 353: 191-198
32. Bergstrom J. D., Kurtz M. M., Rew D. J., Amend A. M., Karkas J. D., Bostedor R. G. et al. (1993) Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA 90: 80-84
33. Bostedor R. G., Karkas J. D., Arison B. H., Bansal V. S., Vaidya S., Germershausen J. I. et al. (1997) Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem. 272: 9197-9203
34. Brown M. S. and Goldstein J. L. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340
35. Brown M. S. and Goldstein J. L. (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc. Natl. Acad. Sci. USA 96: 11041-11048
36. Edwards P. A., Tabor D., Kast H. R. and Venkateswaran A. (2000) Regulation of gene expression by SREBP and SCAP. Biochim. Biophys. Acta 1529: 103-113
37. Osborne T. F. (2000) Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J. Biol. Chem. 275: 32379-32382
38. Schoonjans K., Brendel C., Mangelsdorf D. and Auwerx J. (2000) Sterols and gene expression: control of affluence. Biochim. Biophys. Acta 1529: 114-125
39. Horton J. D., Goldstein J. L. and Brown M. S. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109: 1125-1131
40. Sakakura Y., Shimano H., Sone H., Takahashi A., Inoue N., Toyoshima H. et al. (2001) Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochem. Biophys. Res. Commun. 286: 176-183
41. Tanaka R. D., Schafer B. L., Lee L. Y., Freudenberger J. S. and Mosley S. T. (1990) Purification and regulation of mevalonate kinase from rat liver. J. Biol. Chem. 265: 2391-2398
42. Paton V. G., Shackelford J. E. and Krisans S. K. (1997) Cloning and subcellular localization of hamster and rat isopentenyl diphosphate dimethylallyl diphosphate isomerase. A PTS1 motif targets the enzyme to peroxisomes. J. Biol. Chem. 272: 18945-18950
43. Bishop R. W., Chambliss K. L., Hoffmann G. F., Tanaka R. D. and Gibson K. M. (1998) Characterization of the mevalonate kinase 5′-untranslated region provides evidence for coordinate regulation of cholesterol biosynthesis. Biochem. Biophys. Res. Commun. 242: 518-524
44. Olivier L. M., Chambliss K. L., Gibson K. M. and Krisans S. K. (1999) Characterization of phosphomevalonate kinase: chromosomal localization, regulation and subcellular targeting. J. Lipid Res. 40: 672-679
45. Nakanishi M., Goldstein J. L. and Brown M. S. (1988) Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J. Biol. Chem. 263: 8929-8937
46. Ravid T., Doolman R., Avner R., Harats D. and Roitelman J. (2000) The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 275: 35840-35847
47. Irons M., Elias E. R., Salen G., Tint G. S. and Batta A. K. (1993) Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet 341: 1414
48. Kelley R. I. and Hennekam R. C. (2000) The Smith-Lemli-Opitz syndrome. J. Med. Genet. 37: 321-335
49. FitzPatrick D. R., Keeling J. W., Evans M. J., Kan A. E., Bell J. E., Porteous M. E. et al. (1998) Clinical phenotype of desmosterolosis. Am. J. Med. Genet. 75: 145-152
50. Kelley R. I., Wilcox W. G., Smith M., Kratz L. E., Moser A. and Rimoin D. S. (1999) Abnormal sterol metabolism in patients with Conradi-Hunermann-Happle syndrome and sporadic lethal chondrodysplasia punctata. Am. J. Med. Genet. 83: 213-219
51. Braverman N, Lin P., Moebius F. F., Obie C., Moser A., Glossmann H. et al. (1999) Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hunermann syndrome. Nat. Genet. 22: 291-294
52. Derry J. M., Gormally E., Means G. D., Zhao W., Meindl A., Kelley R. I. et al. (1999) Mutations in a delta 8-delta 7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. Nat. Genet. 22: 286-290
53. Grange D. K., Kratz L. E., Braverman N. E. and Kelley R. I. (2000) CHILD syndrome caused by deficiency of 3beta-hydroxysteroid-delta8, delta7-isomerase. Am. J. Med. Genet. 90: 328-335
54. Konig A., Happle R., Bornholdt D., Engel H. and Grzeschik K. H. (2000) Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am. J. Med. Genet. 90: 339-346
55. Brunetti-Pierri N., Corso G., Rossi M., Ferrari P., Balli F., Rivasi F. et al. (2002) Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am. J. Hum. Genet. 71: 952-958
56. Kelley R. I. and Herman G. E. (2001) Inborn errors of sterol biosynthesis. Annu. Rev. Genomics Hum. Genet. 2: 299-341
57. Kelley R. I., Kratz L. E., Rivka L. G., Netzloff M. I., Wolf L. M. and Jabs E. W. (2002) Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am. J. Med. Genet. 110: 95-102
58. Waterham H. R. (2002) Inherited disorders of cholesterol biosynthesis. Clin. Genet. 61: 393-403
59. Valnot I., von Kleist-Retzow J. C., Barrientos A., Gorbatyuk M., Taanman J. W., Mehaye B. et al. (2000) A mutation in the human heme A: farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum. Mol. Genet. 9: 1245-1249
60. Rotig A., Appelkvist E. L., Geromel V., Chretien D., Kadhom N., Edery P. et al. (2000) Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356: 391-395
61. Pereira-Leal J. B., Hume A. N. and Seabra M. C. (2001) Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett. 498: 197-200
62. Berger R., Smit G. P., Schierbeek H., Bijsterveld K. and le Coultre R. (1985) Mevalonic aciduria: an inborn error of cholesterol biosynthesis? Clin. Chim. Acta 152: 219-222
63. Hoffmann G. F., Charpentier C., Mayatepek E., Mancini J., Leichsenring M., Gibson K. M. et al. (1993) Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91: 915-921
64. Houten S. M., Romeijn G. J., Koster J., Gray R. G., Darbyshire P., Smit G. P. et al. (1999) Identification and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis. Hum. Mol. Genet. 8: 1523-1528
65. Houten S. M., Kuis W., Duran M., de Koning T. J., van Royen-Kerkhof A., Romeijn G. J. et al. (1999) Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22: 175-177
66. Houten S. M., Koster J., Romeijn G. J., Frenkel J., Di Rocco M., Caruso U. et al. (2001) Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur. J. Hum. Genet. 9: 253-259
67. Cuisset L., Drenth J. P., Simon A., Vincent M. F., van der Velde Visser S., van der Meer J. W. et al. (2001) Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur. J. Hum. Genet. 9: 260-266
68. Kelley R. I. (2000) Inborn errors of cholesterol biosynthesis. Adv. Pediatr. 47: 1-53
69. Hinson D. D., Rogers Z. R., Hoffmann G. F., Schachtele M., Fingerhut R., Kohlschutter A. et al. (1998) Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am. J. Med. Genet. 78: 408-412
70. Nimubona L., Laloum D., Rolland M. O., Read M. H., Guillois B. and Duhamel J. F. (2002) An intestinal obstruction in an eight-month-old child suffering from mevalonic aciduria. Acta Paediatr. 91: 714-716
71. Drenth J. P., Haagsma C. J. and van der Meer J. W. (1994) Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73: 133-144
72. Frenkel J., Houten S. M., Waterham H. R., Wanders R. J., Rijkers G. T., Kimpen J. L. et al. (2000) Mevalonate kinase deficiency and Dutch type periodic fever. Clin. Exp. Rheumatol. 18: 525-532
73. van der Meer J. W., Vossen J. M., Radl J., van Nieuwkoop J. A., Meyer C. J., Lobatto S. et al. (1984) Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1: 1087-1090
74. Driesen O., Voute P. A. Jr and Vermeulen A. (1968) A description of two brothers with permanently raised non-esterified aetiocholanolone blood level. Acta Endocrinol. 57: 177-186
75. Prieur A. M. and Griscelli C. (1984) Nosologic aspects of systemic forms of very-early-onset juvenile arthritis. Apropos of 17 cases. Sem. Hop. 60: 163-167
76. Frenkel J., Houten S. M., Waterham H. R., Wanders R. J., Rijkers G. T., Duran M. et al. (2001) Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology 40: 579-584
77. Simon A., Cuisset L., Vincent M. F., van Der Velde-Visser S. D., Delpech M., van Der Meer J. W. et al. (2001) Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-IgD and periodic fever syndrome: its application as a diagnostic tool. Ann. Intern. Med. 135: 338-343
78. Drenth J. P., Vonk A. G., Simon A., Powell R. and van der Meer J. W. (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J. Pharmacol. Exp. Ther. 298: 1221-1226
79. Haas D., Kelley R. I. and Hoffmann G. F. (2001) Inherited disorders of cholesterol biosynthesis. Neuropediatrics 32: 113-122
80. Mayatepek E., Hoffmann G. F. and Bremer H. J. (1993) Enhanced urinary excretion of leukothene E4 in patients with mevalonate kinase deficiency. J. Pediatr. 123: 96-98
81. Frenkel J., Willemsen M. A., Weemaes C. M., Dorland L. and Mayatepek E. (2001) Increased urinary leukothene E(4) during febrile attacks in the hyperimmunoglobulinaemia D and periodic fever syndrome. Arch. Dis. Child. 85: 158-159
82. Mayatepek E., Tiepelmann B. and Hoffmann G. F. (1997) Enhanced excretion of urinary leukothene E4 in mevalonic aciduria is not caused by an impaired peroxisomal degradation of cysteinyl leukothenes. J. Inherit. Metab. Dis. 20: 721-722
83. Schafer B. L., Bishop R. W., Kratunis V. J., Kalinowski S. S., Mosley S. T., Gibson K. M. et al. (1992) Molecular cloning of human mevalonate kinase and identification of a missense mutation in the genetic disease mevalonic aciduria. J. Biol. Chem. 267: 13229-13238
84. Drenth J. P., Cuisset L., Grateau G., Vasseur C., van de Velde-Visser S. D., de Jong J. G. et al. (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 22: 178-181
85. Hinson D. D., Chambliss K. L., Hoffmann G. F., Krisans S., Keller R. K. and Gibson K. M. (1997) Identification of an active site alanine in mevalonate kinase through characterization of a novel mutation in mevalonate kinase deficiency. J. Biol. Chem. 272: 26756-26760
86. Hinson D. D., Ross R. M., Krisans S., Shaw J. L., Kozich V., Rolland M. O. et al. (1999) Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry. Am. J. Hum. Genet. 65: 327-335
87. Houten S. M., van Woerden C. S., Wijburg F. A., Wanders R. J. and Waterham H. R. (2003) Cartier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur. J. Hum. Genet. 11: 196-200
88. Potter D. and Miziorko H. M. (1997) Identification of catalytic residues in human mevalonate kinase. J. Biol. Chem. 272: 25449-25454
89. Potter D., Wojnar J. M., Narasimhan C. and Miziorko H. M. (1997) Identification and functional characterization of an active-site lysine in mevalonate kinase. J. Biol. Chem. 272: 5741-5746
90. Cho Y. K., Rios S. E., Kim J. J. and Miziorko H. M. (2001) Investigation of invariant serine/threonine residues in mevalonate kinase. Tests of the functional significance of a proposed substrate binding motif and a site implicated in human inherited disease. J. Biol. Chem. 276: 12573-12578
91. Kozich V., Gibson K. M., Zeman J., Nemecek J., Hoffman G. F., Pehal F. et al. (1991) Mevalonic aciduria. J. Inherit. Metab. Dis. 14: 265-266
92. Rios S. E., Cho Y. K. and Miziorko H. M. (2001) Characterization of mevalonate kinase V377I, a mutant implicated in defective isoprenoid biosynthesis and HIDS/periodic fever syndrome. Biochim. Biophys. Acta 1531: 165-168
93. Houten S. M., Frenkel J., Rijkers G. T., Wanders R. J., Kuis W. and Waterham H. R. (2002) Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in Hyper-IgD and periodic fever syndrome. Hum. Mol. Genet. 11: 3115-3124
94. Hoffmann G. F., Wiesmann U. N., Brendel S., Keller R. K. and Gibson K. M. (1997) Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Pediatr. Res. 41: 541-546
95. Hubner C., Hoffmann G. F., Charpentier C., Gibson K. M., Finckh B., Puhl H. et al. (1993) Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr. Res. 34: 129-133
96. Gibson K. M., Hoffmann G., Schwall A., Broock R. L., Aramaki S., Sweetman L. et al. (1990) 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium. J. Lipid Res. 31: 515-521
97. Edwards P. A., Lemongello D., Kane J., Shechter I. and Fogelman A. M. (1980) Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J. Biol. Chem. 255: 3715-3725
98. Prendergast G. C. (2000) Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol. 12: 166-173
99. Nantais D. E., Schwemmle M., Stickney J. T., Vestal D. J. and Buss J. E. (1996) Prenylation of an interferon-gamma-induced GTP-binding protein: the human guanylate binding protein, huGBP1. J. Leukoc. Biol. 60: 423-431
100. Keller R. K. and Simonet W. S. (1988) Near normal levels of isoprenoid lipids in severe mevalonic aciduria. Biochem. Biophys. Res. Commun. 152: 857-861
101. Gibson K. M., Stellaard F., Hoffmann G. F., Rating D., Hrebicek M. and Jakobs C. (1993) Bile acid metabolism in three patients with mevalonic aciduria due to mevalonate kinase deficiency. Clin. Chim. Acta 217: 217-220
102. Havenaar E. C., Drenth J. P., van Ommen E. C., van der Meer J. W. and van Dijk W. (1995) Elevated serum level and altered glycosylation of alpha 1-acid glycoprotein in hyperimmunoglobulinemia D and periodic fever syndrome: evidence for persistent inflammation. Clin. Immunol. Immunopathol. 76: 279-284
103. Tsimaratos M., Kone-Paut I., Divry P., Philip N. and Chabrol B. (2001) Mevalonic aciduria and hyper-IgD syndrome: two sides of the same coin? J. Inherit. Metab. Dis. 24: 413-414
104. Klasen I. S., Goertz J. H., van de Wiel G. A., Weemaes C. M., van der Meer J. W. and Drenth J. P. (2001) Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome. Clin. Diagn. Lab. Immunol. 8: 58-61
105. Drenth J. P., Goertz J., Daha M. R. and van der Meer J. W. (1996) Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 88: 355-362
106. Haraldsson A., Weemaes C. M., De Boer A. W., Bakkeren J. A. and Stoelinga G. B. (1992) Immunological studies in the hyper-immunoglobulin D syndrome. J. Clin. Immunol. 12: 424-428
107. Vladutiu A. O. (2000) Immunoglobulin D: properties, measurement, and clinical relevance. Clin. Diagn. Lab. Immunol. 7: 131-140
108. Drenth J. P., Powell R. J., Brown N. S. and Van der Meer J. W. (1995) Interferon-gamma and urine neopterin in attacks of the hyperimmunoglobulinaemia D and periodic fever syndrome. Eur. J. Clin. Invest. 25: 683-686
109. Drenth J. P., van Deuren M., van der Ven-Jongekrijg J., Schalkwijk C. G. and van der Meer J. W. (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 85: 3586-3593
110. Drenth J. P., van der Meer J. W. and Kushner I. (1996) Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J. Immunol. 157: 400-404
111. Levan-Petit I., Lelievre E., Barra A., Limosin A., Gombert B., Preud'homme J. L. et al. (1999) T(h)2 cytokine dependence of IgD production by normal human B cells. Int. Immunol. 11: 1819-1828
112. Levy B. D., Petasis N. A. and Serhan C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389: 985-990
113. Tansey T. R. and Shechter I. (2000) Structure and regulation of mammalian squalene synthase. Biochim. Biophys. Acta 1529: 49-62
114. Feingold K. R., Hardardottir I., Memon R., Krul E. J., Moser A. H., Taylor J. M. et al. (1993) Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J. Lipid Res. 34: 2147-2158
115. Feingold K. R., Pollock A. S., Moser A. H., Shigenaga J. K. and Grunfeld C. (1995) Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J. Lipid Res. 36: 1474-1482
116. Memon R. A., Shechter I., Moser A. H., Shigenaga J. K., Grunfeld C. and Feingold K. R. (1997) Endotoxin, tumor necrosis factor and interleukin-1 decrease hepatic squalene synthase activity, protein and mRNA levels in Syrian hamsters. J. Lipid Res. 38: 1620-1629
117. McFarlane S. I., Muniyappa R., Francisco R. and Sowers J. R. (2002) Pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87: 1451-1458
118. Werner N., Nickenig G. and Laufs U. (2002) Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97: 105-116
119. Liao J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110: 285-288
120. Weitz-Schmidt G. (2002) Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23: 482-486
121. Vaughan C. J., Murphy M. B. and Buckley B. M. (1996) Statins do more than just lower cholesterol. Lancet 348: 1079-1082
122. Massy Z. A., Keane W. F. and Kasiske B. L. (1996) Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347: 102-103
123. Sinensky M., Beck L. A., Leonard S. and Evans R. (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J. Biol. Chem. 265: 19937-19941
124. Hinson D. D., Chambliss K. L., Toth M. J., Tanaka R. D. and Gibson K. M. (1997) Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and non-sterol isoprene biosynthetic pathways. J. Lipid Res. 38: 2216-2223
125. Sadeghi M. M., Collinge M., Pardi R. and Bender J. R. (2000) Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165: 2712-2718
126. Montero M. T., Hernandez O., Suarez Y., Matilla J., Ferruelo A. J., Martinez-Botas J. et al. (2000) Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153: 303-313
127. Kiener P. A., Davis P. M., Murray J. L., Youssef S., Rankin B. M. and Kowala M. (2001) Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol. 1: 105-118
128. Frenkel J., Rijkers G. T., Mandey S. H., Buurman S. W., Houten S. M., Wanders R. J. et al. (2002) Lack of isoprenoid products raises ex vivo interleukin-1β secretion in Hypermmunoglobulinemia D periodic fever syndrome. Arthritis Rheum. 46: 2794-2803
129. Galon J., Aksentijevich I., McDermott M. F., O'Shea J. J. and Kastner D. L. (2000) TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 12: 479-486
130. Drenth J. P. and van der Meer J. W. (2001) Hereditary periodic fever. N. Engl. J. Med. 345: 1748-1757
131. Kastner D. L. and O'Shea J. J. (2001) A fever gene comes in from the cold. Nat. Genet. 29: 241-242
132. Hoffman H. M., Mueller J. L., Broide D. H., Wanderer A. A. and Kolodner R. D. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29: 301-305
133. Feldmann J., Prieur A. M., Quartier P., Berquin P., Certain S., Cortis E. et al. (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71: 198-203
134. McDermott M. F., Aksentijevich I., Galon J., McDermott E. M., Ogunkolade B. W., Centola M. et al. (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97: 133-144
135. The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat. Genet. 17: 25-31
136. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90: 797-807
137. Bertin J. and DiStefano P. S. (2000) The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ. 7: 1273-1274
138. Fairbrother W. J., Gordon N. C., Humke E. W., O'Rourke K. M., Starovasnik M. A., Yin J. P. et al. (2001) The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci. 10: 1911-1918
139. Martinon F., Hofmann K. and Tschopp J. (2001) The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr. Biol. 11: R118-120
140. Pawlowski K., Pio F., Chu Z., Reed J. C. and Godzik A. (2001) PAAD - a new protein domain associated with apoptosis, cancer and autoimmune diseases. Trends Biochem. Sci. 26: 85-87
141. Gumucio D. L., Diaz A., Schaner P., Richards N., Babcock C., Schaller M. et al. (2002) Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin. Exp. Rheumatol. 20: S45-53
142. Martinon F., Burns K. and Tschopp J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10: 417-426
143. Srinivasula S. M., Poyet J. L., Razmara M., Datta P., Zhang Z. and Alnemri E. S. (2002) The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277: 21119-21122
144. Dode C., Le Du N., Cuisset L., Letourneur F., Berthelot J. M., Vaudour G. et al. (2002) New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold Urticaria: a novel mutation underlies both syndromes. Am. J. Hum. Genet. 70: 1498-1506